Patents by Inventor Boris Minev

Boris Minev has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11918604
    Abstract: The current invention provides monocytic cells transfected with chimeric antigen receptor (CAR) to selectively home to tumors and upon homing differentiate into dendritic cells capable of activating immunity which is inhibitory to said tumor. In one embodiment of the invention, monocytic cells are transfected with a construct encoding an antigen binding domain, a transcellular or structural domain, and an intracellular signaling domain. In one specific aspect of the invention, the antigen binding domain interacts with sufficient affinity to a tumor antigen, capable of triggering said intracellular domain to induce an activation signal to induce monocyte differentiation into DC.
    Type: Grant
    Filed: April 7, 2022
    Date of Patent: March 5, 2024
    Assignee: MYELOID THERAPEUTICS, INC.
    Inventors: Samuel C. Wagner, Thomas E. Ichim, Julia S. Szymanski, Santosh Kesari, Amit N. Patel, Boris Minev
  • Patent number: 11918605
    Abstract: The current invention provides monocytic cells transfected with chimeric antigen receptor (CAR) to selectively home to tumors and upon homing differentiate into dendritic cells capable of activating immunity which is inhibitory to said tumor. In one embodiment of the invention, monocytic cells are transfected with a construct encoding an antigen binding domain, a transcellular or structural domain, and an intracellular signaling domain. In one specific aspect of the invention, the antigen binding domain interacts with sufficient affinity to a tumor antigen, capable of triggering said intracellular domain to induce an activation signal to induce monocyte differentiation into DC.
    Type: Grant
    Filed: October 27, 2022
    Date of Patent: March 5, 2024
    Assignee: MYELOID THERAPEUTICS, INC.
    Inventors: Samuel C. Wagner, Thomas E. Ichim, Julia S. Szymanski, Santosh Kesari, Amit N. Patel, Boris Minev
  • Publication number: 20230173062
    Abstract: Disclosed herein are methods and compositions related to therapy for cancer. More specifically, the disclosed methods and compositions are related to the use of smallpox vaccine to induce an effective anti-tumor immune response.
    Type: Application
    Filed: January 30, 2023
    Publication date: June 8, 2023
    Inventors: Aladar SZALAY, Boris Minev
  • Patent number: 11607450
    Abstract: Disclosed herein are methods and compositions related to therapy for cancer. More specifically, the disclosed methods and compositions are related to the use of smallpox vaccine to induce an effective anti-tumor immune response.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: March 21, 2023
    Assignee: Calidi Biotherapeutics, Inc.
    Inventors: Aladar Szalay, Boris Minev
  • Patent number: 11517589
    Abstract: The current invention provides monocytic cells transfected with chimeric antigen receptor (CAR) to selectively home to tumors and upon homing differentiate into dendritic cells capable of activating immunity which is inhibitory to said tumor. In one embodiment of the invention, monocytic cells are transfected with a construct encoding an antigen binding domain, a transcellular or structural domain, and an intracellular signaling domain. In one specific aspect of the invention, the antigen binding domain interacts with sufficient affinity to a tumor antigen, capable of triggering said intracellular domain to induce an activation signal to induce monocyte differentiation into DC.
    Type: Grant
    Filed: April 7, 2022
    Date of Patent: December 6, 2022
    Assignee: Myeloid Therapeutics, Inc.
    Inventors: Samuel C. Wagner, Thomas E. Ichim, Julia S. Szymanski, Santosh Kesari, Amit N. Patel, Boris Minev
  • Publication number: 20220249552
    Abstract: The current invention provides monocytic cells transfected with chimeric antigen receptor (CAR) to selectively home to tumors and upon homing differentiate into dendritic cells capable of activating immunity which is inhibitory to said tumor. In one embodiment of the invention, monocytic cells are transfected with a construct encoding an antigen binding domain, a transcellular or structural domain, and an intracellular signaling domain. In one specific aspect of the invention, the antigen binding domain interacts with sufficient affinity to a tumor antigen, capable of triggering said intracellular domain to induce an activation signal to induce monocyte differentiation into DC.
    Type: Application
    Filed: April 7, 2022
    Publication date: August 11, 2022
    Inventors: Samuel C. Wagner, Thomas E. Ichim, Julia S. Szymanski, Santosh Kesari, Amit N. Patel, Boris Minev
  • Publication number: 20220241388
    Abstract: Disclosed herein are methods and compositions related to combination therapy for cancer. More specifically, several treatment modalities are used in combination to induce an effective anti-tumor immune response.
    Type: Application
    Filed: March 8, 2022
    Publication date: August 4, 2022
    Inventors: Aladar SZALAY, Boris MINEV
  • Publication number: 20220233586
    Abstract: The current invention provides monocytic cells transfected with chimeric antigen receptor (CAR) to selectively home to tumors and upon homing differentiate into dendritic cells capable of activating immunity which is inhibitory to said tumor. In one embodiment of the invention, monocytic cells are transfected with a construct encoding an antigen binding domain, a transcellular or structural domain, and an intracellular signaling domain. In one specific aspect of the invention, the antigen binding domain interacts with sufficient affinity to a tumor antigen, capable of triggering said intracellular domain to induce an activation signal to induce monocyte differentiation into DC.
    Type: Application
    Filed: April 7, 2022
    Publication date: July 28, 2022
    Inventors: Samuel C. Wagner, Thomas E. Ichim, Julia S. Szymanski, Santosh Kesari, Amit N. Patel, Boris Minev
  • Publication number: 20220202856
    Abstract: The current invention provides monocytic cells transfected with chimeric antigen receptor (CAR) to selectively home to tumors and upon homing differentiate into dendritic cells capable of activating immunity which is inhibitory to said tumor in one embodiment of the invention, monocytic cells are transfected with a construct encoding an antigen binding domain, a transcellular or structural domain, and an intracellular signaling domain. In one specific aspect of the invention, the antigen binding domain interacts with sufficient affinity to a tumor antigen, capable of triggering said intracellular domain to induce an activation signal to induce monocyte differentiation into DC.
    Type: Application
    Filed: February 15, 2022
    Publication date: June 30, 2022
    Inventors: Samuel C. WAGNER, Thomas E. Ichim, Julia S. Szymanski, Santosh Kesari, Amit N. Patel, Boris Minev
  • Publication number: 20220175830
    Abstract: The current invention provides monocytic cells transfected with chimeric antigen receptor (CAR) to selectively home to tumors and upon homing differentiate into dendritic cells capable of activating immunity which is inhibitory to said tumor. In one embodiment of the invention, monocytic cells are transfected with a construct encoding an antigen binding domain, a transcellular or structural domain, and an intracellular signaling domain. In one specific aspect of the invention, the antigen binding domain interacts with sufficient affinity to a tumor antigen, capable of triggering said intracellular domain to induce an activation signal to induce monocyte differentiation into DC.
    Type: Application
    Filed: February 18, 2022
    Publication date: June 9, 2022
    Inventors: Samuel C. WAGNER, Thomas E. Ichim, Julia S. Szymanski, Santosh Kesari, Amit N. Patel, Boris Minev
  • Publication number: 20220175831
    Abstract: The current invention provides monocytic cells transfected with chimeric antigen receptor (CAR) to selectively home to tumors and upon homing differentiate into dendritic cells capable of activating immunity which is inhibitory to said tumor. In one embodiment of the invention, monocytic cells are transfected with a construct encoding an antigen binding domain, a transcellular or structural domain, and an intracellular signaling domain. In one specific aspect of the invention, the antigen binding domain interacts with sufficient affinity to a tumor antigen, capable of triggering said intracellular domain to induce an activation signal to induce monocyte differentiation into DC.
    Type: Application
    Filed: February 18, 2022
    Publication date: June 9, 2022
    Inventors: Samuel C. WAGNER, Thomas E. Ichim, Julia S Szymanski, Santosh Kesari, Amit N. Patel, Boris Minev
  • Publication number: 20220118010
    Abstract: The current invention provides monocytic cells transfected with chimeric antigen receptor (CAR) to selectively home to tumors and upon homing differentiate into dendritic cells capable of activating immunity which is inhibitory to said tumor. In one embodiment of the invention, monocytic cells are transfected with a construct encoding an antigen binding domain, a transcellular or structural domain, and an intracellular signaling domain, In one specific aspect of the invention, the antigen binding domain interacts with sufficient affinity to a tumor antigen, capable of triggering said intracellular domain to induce an activation signal to induce monocyte differentiation into DC.
    Type: Application
    Filed: December 22, 2021
    Publication date: April 21, 2022
    Inventors: Samuel C. WAGNER, Thomas E. Ichim, Julia S. Szymanski, Santosh Kesari, Amit N. Patel, Boris Minev
  • Patent number: 11285194
    Abstract: Disclosed herein are methods and compositions related to combination therapy for cancer. More specifically, several treatment modalities are used in combination to induce an effective anti-tumor immune response. The present invention relates generally to the treatment of human cancer and, more specifically, to use of several treatment modalities in combination to induce effective anti-tumor immune responses.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: March 29, 2022
    Assignee: Calidi Biotherapeutics, Inc.
    Inventors: Aladar Szalay, Boris Minev
  • Publication number: 20210252053
    Abstract: The current invention provides monocytic cells transfected with chimeric antigen receptor (CAR) to selectively home to tumors and upon homing differentiate into dendritic cells capable of activating immunity which is inhibitory to said tumor. In one embodiment of the invention, monocytic cells are transfected with a construct encoding an antigen binding domain, a transcellular or structural domain, and an intracellular signaling domain. In one specific aspect of the invention, the antigen binding domain interacts with sufficient affinity to a tumor antigen, capable of triggering said intracellular domain to induce an activation signal to induce monocyte differentiation into DC.
    Type: Application
    Filed: April 9, 2021
    Publication date: August 19, 2021
    Inventors: Samuel C. Wagner, Thomas E. Ichim, Julia S. Szymanski, Santosh Kesari, Amit N. Patel, Boris Minev
  • Publication number: 20210046178
    Abstract: Disclosed herein are methods and compositions related to therapy for cancer. More specifically, the disclosed methods and compositions are related to the use of smallpox vaccine to induce an effective anti-tumor immune response.
    Type: Application
    Filed: November 4, 2020
    Publication date: February 18, 2021
    Inventors: Aladar Szalay, Boris Minev
  • Patent number: 10857225
    Abstract: Disclosed herein are methods and compositions related to therapy for cancer. More specifically, the disclosed methods and compositions are related to the use of smallpox vaccine to induce an effective anti-tumor immune response.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: December 8, 2020
    Assignee: Calidi Biotherapeutics, Inc.
    Inventors: Aladar Szalay, Boris Minev
  • Patent number: 10238700
    Abstract: Provided are adjunct therapies for use in combinations and compositions with an oncolytic virus, such as a vaccinia virus. The adjunct therapies include co-administration and co-formulation of a complement inhibitor and/or a lipid emulsion composition with the oncolytic virus. Also provided herein are therapeutic methods using the adjunct therapies for treatment of disease and conditions employing an oncolytic therapeutic virus, such as for the treatment of hyperproliferative diseases or conditions including tumors or cancers.
    Type: Grant
    Filed: December 31, 2014
    Date of Patent: March 26, 2019
    Assignee: Genelux Corporation
    Inventors: Aladar A. Szalay, Joseph Cappello, Nanhai G. Chen, Boris Minev
  • Publication number: 20180325948
    Abstract: Treatment of cancer is disclosed through administration of proteins or specific peptides that are uptaken by dendritic cells, wherein said dendritic cells as subsequently activated and administered, in vivo, in a matter eliciting monocyte or dendritic cell migration in order to allow uptake of said administrated proteins or peptides, followed by administration of a maturation signal in vivo. Alternatively said immature dendritic cells are grown ex vivo in an autologous or semiallogenenic manner derived utilizing conventional means and pulsed with tumor peptides disclosed herein and subsequently administered. In some embodiments of the invention said dendritic cells are treated with epigenetic modifiers to enhance antigen presentation. The invention provides for treatment of cancer through induction of anticancer immunity and/or immunity towards tumor associated blood vessels.
    Type: Application
    Filed: November 14, 2016
    Publication date: November 15, 2018
    Inventors: Thomas ICHIM, JOSE JAVIER LOPEZ GONZALEZ, Santosh KESARI, Boris MINEV
  • Publication number: 20180326048
    Abstract: Disclosed herein are methods and compositions related to therapy for cancer. More specifically, the disclosed methods and compositions are related to the use of smallpox vaccine to induce an effective anti-tumor immune response.
    Type: Application
    Filed: July 24, 2018
    Publication date: November 15, 2018
    Inventors: Aladar Szalay, Boris Minev
  • Patent number: 10105436
    Abstract: Disclosed herein are methods and compositions related to therapy for cancer. More specifically, the disclosed methods and compositions are related to the use of smallpox vaccine to induce an effective anti-tumor immune response.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: October 23, 2018
    Assignee: Calidi Biotherapeutics, Inc.
    Inventors: Aladar Szalay, Boris Minev